1900755-49-8

Basic information

• Product Name: (1-trityl-1H-imidazol-4-yl)boronic acid
• CAS NO: 1900755-49-8
• Molecular Weight: 354.216
• Mol File: 1900755-49-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (1-trityl-1H-imidazol-4-yl)boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1-trityl-1H-imidazol-4-yl)boronic acid(1900755-49-8)
• EPA Substance Registry System: (1-trityl-1H-imidazol-4-yl)boronic acid(1900755-49-8)

Safety Data

• Hazardous Substances Data: 1900755-49-8(Hazardous Substances Data)

Usage

General Description

(1-trityl-1H-imidazol-4-yl)boronic acid is a boronic acid derivative with the chemical formula C20H18BNO2. It is a white to off-white powder that is used in organic synthesis as a reagent for the Suzuki-Miyaura cross-coupling reaction, which is a widely used method for the formation of carbon-carbon bonds. (1-trityl-1H-imidazol-4-yl)boronic acid is also utilized in the pharmaceutical industry for the development of new drug molecules, as it can be used to modify the structure of biologically active compounds. Additionally, (1-trityl-1H-imidazol-4-yl)boronic acid has applications in material science and catalysis due to its ability to form stable complexes with a variety of organic molecules. Overall, this chemical plays a crucial role in the field of organic chemistry and has a wide range of potential applications.

Upstream product

• 76-83-5 trityl chloride 
• 121-43-7 Trimethyl borate 
• 96797-15-8 N-trityl-4⁽⁵⁾-iodoimidazole 

Downstream Products

• 1021949-47-2 1-(4-imidazolyl)-1-(2,3-dimethylphenyl)ethylene 

Relevant articles and documents

SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS

The present invention relates to novel substituted [5,6]cyclic-4(3H)-pyrimidinone compounds of formula (I) and their preparation methods. (I) In particular, the present invention relates to novel substituted [5,6]cyclic-4(3H)- pyrimidinone compounds useful as inhibitors of protein kinases, specifically CDC7 (cell division cycle 7) inhibitors.

6,7-HETEROCYCLIC FUSED 5H-PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES AND THEIR USE AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TD02) MODULATORS

This invention relates to novel compounds of formula (I) wherein 'A' is a 5 or 6 membered heteroaryl group, unsubstituted or substituted with 1, 2 or 3 groups as defined in claim 1; X is a bond or -(CRA1RB1)n-; Y is selected from: a bond, -(CRDRE)m-, -O-, -NRF, -S-, -C(O)-, -C(NRF) -, -C(ORF)Rc-, -C(NRFRG)RC-, -C(O)NRF, -NRFC(O)-, -NRFC(O)NRG-, - NRFSO2NRG-, -SO2-, -SO2NRF-, -NRFSO2-, -OC(O)- and -C(O)O-; Z is a bond or -(CRA2RB2)k-; wherein m, n and k are each independently selected from 1, 2, 3 and 4; R1 is H or a 3 to 16 membered fully saturated, partially unsaturated or aromatic mono-, di- or tri-cyclic moiety, which optionally may include 1, 2 or 3 heteroatoms selected from O, N and S, and which is unsubstituted or substituted with 1 to 5 substituents as defined in claim 1; R2 is selected from: H, halo, C1-4alkyl, C1-4 haloalkyl, -ORA4 and C1-4alkyl substituted with -ORA4; and R3 and R4 are each independently selected from: H, halo, C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, -ORA4, -NRA5RB4, -CN, -SRAS and C1-4alkyl substituted with -ORA5; and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3- dioxygenase (TD02) modulators (e.g. IDOl, and ID02 and/or TD02 inhibitors).